Copper-64

Properties

Cu has a half-life of 12.70 hours and decays 61.5% of the time to Ni, of which 17.5% is positron emission and 44% by electron capture, and 38.5% by beta decay to Zn. The electron-capture branch emits a 1.346-MeV gamma ray in 0.472% of all decays, which could be used for tracing the isotope.

Production

Copper-64 can be produced by several different methods with the most common methods using either a reactor or a particle accelerator. Thermal neutrons can produce Cu in low specific activity (the number of decays per second per amount of substance) and low yield through the Cu(n,γ)Cu reaction. At the University of Missouri Research Reactor Center (MURR) Cu was produced using high-energy neutrons via the Zn(n,p)Cu nuclear reaction in high specific activity but low yield. Using a biomedical cyclotron the Ni(p,n)Cu nuclear reaction can produce large quantities of the nuclide with high specific activity.

Applications

As a positron emitter, Cu has been used to produce experimental and clinical radiopharmaceuticals for the imaging of a range of conditions. Its beta emissions also raise the possibility of therapeutic applications. Compared to typical PET radionuclides it has a relatively long half-life, which can be advantageous for therapy, and for imaging certain physiological processes.

PET imaging

Bone metastases

Experimental preclinical work has shown that Cu linked to methanephosphonate functional groups has potential as a bone imaging agent.

Neuroendocrine tumors (NETs)

Neuroendocrine tumors (NETs) are localised clinically using a range of DOTA based radiopharmaceuticals. For PET imaging these are typically Gallium-68 based. A commercial Cu-DOTA-TATE product has been FDA approved for localization of somatostatin receptor positive NETs since 2020.

Prostate cancer

The Bombesin peptide has been shown to be overexpressed in BB2 receptors in prostate cancer. CB-TE2A a stable chelation system for Cu was incorporated with Bombesin analogs for in vitro and in vivo studies of prostate cancer. PET-CT imagining studies showed that it underwent uptake into prostate tumor xenografts selectively with decreased uptake into non target tissues. Other preclinical studies have shown that by targeting the gastrin-releasing peptide receptor pancreatic and breast cancer can also be detected.

Renal perfusion

Ethylglyoxal bis(thiosemicarbazone) (ETS) has potential utility as a PET radiopharmaceutical with the various isotopes of copper. Cu-ETS has been used for experimental preclinical myocardial, cerebral and tumor perfusion evaluations, with a linear relationship between the renal uptake and blood flow. Renal perfusion can also be evaluated with CT or MRI instead of PET, but with drawbacks: CT requires administration of potentially allergenic contrast agents. MRI avoids use of ionising radiation but is difficult to implement, and often suffers from motion artefacts. PET with Cu can offer quantitative measurements of renal perfusion.

Wilson’s disease

Wilson disease is a rare condition in which copper is retained excessively in the body. Toxic levels of copper can lead to organ failure and premature death. Cu has been used experimentally to study whole body retention of copper in subjects with this disease. The technique can also separate heterozygous carriers and homozygous normals.

Cancer therapy

Cu-ATSM (diacetyl-bis(N4-methylthiosemicarbazone)) has been shown to increase the survival time of tumor-bearing animals. Areas of low oxygen retention have been shown to be resistant to external beam radiotherapy because hypoxia reduces the lethal effects of ionizing radiation. Cu was believed to kill these cells because of its unique decay properties. In animal models having colorectal tumors with and without induced hypoxia, Cu-ATSM was preferentially taken up by hypoxic cells over normoxic cells. The results demonstrated that this compound increased survival of the tumor bearing hamsters compared with controls.

References

References

1. {{AME2020 II
2. {{NUBASE2020
3. {{NNDC
4. Less than the actual decay energy by that released in [[annihilation]].
5. (2003). "Handbook of Radiopharmaceuticals : radiochemistry and applications". Wiley.
6. (2016). "Cyclotron Produced Radionuclides: Emerging Positron Emitters for Medical Applications: 64Cu and 124I". [[International Atomic Energy Agency]].
7. (2 October 2018). "Copper-64: a real theranostic agent". Drug Design, Development and Therapy.
8. (1 January 2019). "64 Cu-based Radiopharmaceuticals in Molecular Imaging". Technology in Cancer Research & Treatment.
9. (1 January 2003). "In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands". Journal of Biological Inorganic Chemistry.
10. "DETECTNET". [[Food and Drug Administration]].
11. (2 September 2020). "Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy". Molecules.
12. (13 July 2006). "MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor". Breast Cancer Research and Treatment.
13. (April 2007). "Assessment of Cu-ETS2 as a PET radiopharmaceutical for evaluation of regional renal perfusion". Nuclear Medicine and Biology.
14. (2003). "Handbook of Radiopharmaceuticals: Radiochemistry and Applications". John Wiley & Sons.
15. (2018). "Animal models of Wilson disease". Journal of Neurochemistry.
16. (30 January 2001). "Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy". Proceedings of the National Academy of Sciences.